我們已在上線！進一步了解

Amneal Pharmaceuticals

AMRX

市值 US$66.8億

19.18 USD

-0.07

0.36%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

19.75

+0.57

2.97%

1天

-0.36%

5天

-4.29%

1個月

6.08%

3個月

6.32%

6個月

46.52%

今年迄今

51.5%

1年

94.33%

5年

243.73%

10年

27.78%

關於： Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

員工： 8,500

醫療保健藥品製造商－特殊及學名藥

新聞

正面

中性

負面

市場情緒 3個月

正面 40.9%

中性 54.5%

負面 4.5%

Amneal to Report Third Quarter 2026 Results on November 3, 2026

BRIDGEWATER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report third quarter 2026 financial results on Tuesday, November 3, 2026, before market open. The Company will host an audio webcast at 8:30 a.m. ET.

Amneal to Report Third Quarter 2026 Results on November 3, 2026

Amneal Announces FDA Approval and Launch of Lanreotide Injection

- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production

Amneal Announces FDA Approval and Launch of Lanreotide Injection

Zacks Investment Research

Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?

Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?

Zacks Investment Research

5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low

COCO, DAR, CNC, EXC and AMRX offer a defensive appeal as consumer confidence hits a 7-month low amid inflation and labor market concerns.

5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low

Zacks Investment Research

4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike

A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.

4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike

STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)---- $AMRX #AMRX--Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) on behalf of the company's current shareholders.The investigation seeks to determine whether Amneal or the company's officers and/or directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.Amneal shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional informat.

STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm

Zacks Investment Research

5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns

Five stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exceeding industry averages.

5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns

Zacks Investment Research

Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?

Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosion and execution risks raise the stakes.

Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?

Zacks Investment Research

Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?

AMRX's Kashiv deal creates an integrated biosimilars platform, but integration, regulatory execution and product uptake remain key.

Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?

Zacks Investment Research

AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?

Amneal 44.8% rally faces a test as earnings, launches and pipeline progress contend with Rytary erosion and a higher historical valuation.

AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?

查看新聞排名

價格圖表採用Lightweight Charts™實作